Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Holding ITCI?
Track your performance easily
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$57.68 - $93.45
Previous Close$83.35
Volume229.26K
Average Volume (3M)561.45K
Market Cap
$9.09B
Enterprise Value$7.85B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$17.71M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Feb 26, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding106,017,103
10 Day Avg. Volume709,432
30 Day Avg. Volume561,448
Standard Deviation0.35
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)7.72
Price to Sales (P/S)14.43
Price to Cash Flow (P/CF)-82.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.80
Enterprise Value/Gross Profit18.32
Enterprise Value/Ebitda-130.09
Forecast
1Y Price Target
$100.77Price Target Upside17.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Intra-Cellular Therapies News
Bulls Say, Bears Say
Bulls Say
Market ExpansionCaplyta should be able to ramp faster in the MDD market due to increased physician awareness and resourcing compared to previous extensions.
Pipeline PotentialThe ongoing ITI-1284 trials could add significant value in neuropsych disorders, with a potential $1 billion peak sales opportunity.
Sales GrowthManagement announced for the first time that it expects Caplyta could achieve $5B in peak sales, which is above the current $3.6B estimate.
Bears Say
EarningsEarnings per share came in lower than expected.
Financial PerformanceGAAP EPS was -$0.25, slightly below consensus of -$0.18, driven by higher SG&A and R&D expenses.
Operating ExpensesTotal operating expenses were higher than consensus estimates.
---
Ownership Overview
1.24% Insiders
31.02% Mutual Funds
29.98% Other Institutional Investors
24.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $57.67 and its highest was $93.45 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is Feb 26, 2025 which is in 98 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on Oct 30, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.179 by -$0.071.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.06.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 106,017,105 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.179. Following the earnings report the stock price went up 11.362%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Perceptive Advisors LLC. It holds Intra-Cellular Therapies’s shares valued at 126M.
---
Intra-Cellular Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.77 (17.50% Upside)
$100.77 (17.50% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 11.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.74%
12-Months-Change
Fundamentals
Return on Equity
-9.90%
Trailing 12-Months
Asset Growth
84.55%
Trailing 12-Months
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
ITCI Earnings Call
Q3 2024
0:00 / 0:00
---
ITCI Stock 12 Month Forecast
Average Price Target
$100.77
▲(17.50% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
SAGE Therapeutics
―
Viking Therapeutics
―
Best Analysts Covering ITCI
1 Year
1 Year Success Rate
28/29 ratings generated profit
1 Year Average Return
+31.29%
assigned a buy rating 30 days ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 96.55% of your transactions generating a profit, with an average return of +31.29% per trade.
---